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Sir,
Sneddon’s Syndrome is a rare and poorly understood
syndrome characterized by the association of ischemic
cerebrovascular events and livedo racemosa [1]. We report
a case of a 35-year-old woman with Sneddon’s Syndrome
and digital ulcers successfully treated with Bosentan.
Patient was admitted to our center with pain and trophic
ulcers in both hands and feet, Raynaud’s phenomenon,
livedo racemosa on the extremities, headache and memory
loss. Her past medical history was notable for Cushing
syndrome treated with total hypophysectomy and bilateral
adrenalectomy, a history of recurrent miscarriage and
hypertension under treatment. Physical examination was
normal except for the skin lesions. The search for anti-
phospholipid antibodies [anticardiolipin (aCL), anti-beta2GPI
and lupus anticoagulant (LA)], antinuclear autoantibodies
(ANA), anti-extractable nuclear antigens (ENA) and anti-
double-stranded DNA (anti-dsDNA) was negative. Cere-
bral MRI showed multiple subcortical and periventricular
lesions suggestive of previous ischemic events. In the light
of these findings, a carotid ultrasonography and an echo-
cardiography were performed to rule out micro embolism.
Echocardiography showed a partial thickening of the mitral
valve. Livedo racemosa was confirmed by a skin biopsy
showing a light leukocyte infiltrate and capillary dilatation.
The diagnosis of Sneddon’s Syndrome was made. Due to
the lack of ulcer’s healing with conventional therapies we
decided to replace iloprost pulse therapy with Bosentan
treatment. Bosentan is a dual endothelin-1 (ET-1) receptor
antagonist with affinity for both ET-1 A and ET-1 B
receptors. ET-1 is one of the most powerful vasoconstrictor
agents [2], able to induce fibrosis and cellular proliferation.
Fig. 1 Patient’s livedo and trophic ulcers before (left) and after
(right) Bosentan treatment
T. Barnini (&)  E. Silvestri  G. Emmi 
M. M. D’Elios  L. Emmi
SOD Patologia Medica, Center for Autoimmune Diseases,
Lupus Clinic, DAI Biomedicina, AOU Careggi,
Largo Giovanni Brambilla 3, 50134 Florence, Italy
e-mail: tommasobarnini@gmail.com
123
Autoimmun Highlights (2013) 4:67–68
DOI 10.1007/s13317-012-0037-0
These effects were mediated by the ET-1 binding on both
receptors in vascular smooth muscle cells. Bosentan has
been approved by the European Medicines Agency (EMA)
for the prevention of new digital ulcer formation in Sys-
temic Sclerosis (SS) [3]. A recent study on patients with SS
demonstrated a 30 % reduction of new digital ulcers during
treatment with Bosentan but no healing of active ulcers was
observed [4].
In our patient, a few weeks after the start of Bosentan
administration, ulcers rapidly healed, with an important
reduction of pain and livedo (Fig. 1). Clinical conditions
remained good and no new ulcers developed over the next
6 months.
To our knowledge, this is the first case of Sneddon’s
Syndrome treated with Bosentan; in contrast to that
reported in SS, Bosentan led to a complete healing of pre-
existing cutaneous ulcers.
The success of this anti-endothelial proliferative drug
supports the hypothesis [5] that an endothelial proliferation
could be the main pathophysiological mechanism of this
obliterative vasculopathy.
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